Please select the option that best describes you:
What are your top takeaways in GU Cancers from ESMO 2025?
Answer from: Medical Oncologist at Academic Institution
KEYNOTE-905: These impressive results change the management paradigm of patients with MIBC who are surgical candidates but are not cisplatin-eligible. Over time, it may be that EVP perioperative therapy becomes the standard of care for all patients with MIBC with plans to proceed with cystectomy.
...
Sign In or Register to read more
Answer from: Medical Oncologist at Academic Institution
EV-303/KEYNOTE-905: Peri-operative EV/pembrolizumab in cisplatin-ineligible patients with MIBC.
IMvigor011: Adjuvant atezolizumab vs placebo based on ctDNA.
RC48-C016 (China): Disitamab vedotin + toripalimab vs gemcitabine + (cisplatin or carboplatin) in the frontline metastatic urothelial Ca se...
Answer from: Medical Oncologist at Academic Institution
EV-303: Practice-changing trial with EV/Pembro now potentially becoming the new SOC for cisplatin-ineligible patients with MIBC.
Imvigor011: First trial showing ctDNA to be a predictive biomarker for ICI treatment in patients with high-risk MIBC following cystectomy. Also first trial to show OS a...
Answer from: Medical Oncologist at Community Practice
I think all 3 of the Presidential Symposium presentations were impactful - EV-303, IMvigor011, and the DV + toripalimab:
EV-303 is practice-changing once approved.
IMvigor011 shows the value of assigning therapy based on ctDNA, and
DV study, while done in China, had an impressive ORR and PFS/OS, ...